Proteros Biostructures GmbH provides structure-based early stage drug discovery services, combining protein sciences, structural biology, biophysics and screening for challenging targets.
Proteros Biostructures GmbH is a Munich-headquartered provider of structure-based early stage drug discovery services. The company works on technically difficult drug targets - among them multi-subunit protein complexes, membrane proteins, GPCRs and ion channels - and covers the path from target validation through to lead progression. Its discovery engine combines protein sciences, structural biology, biophysics and screening capabilities within a single organisation.
The firm's scientific foundations rest on Nobel prize-winning science, and it positions itself around reliable results and excellence in project execution. Proteros states that it works to accelerate its clients' research timelines, with an emphasis on agile interaction and close alignment to customer needs. It has partnerships with more than 200 pharmaceutical and biotechnology companies worldwide.
Proteros serves customers across Europe and North America from its base in Munich, Germany. Its work sits within the pharmaceutical and biotechnology sectors, specifically early stage research and development.
